SlideShare ist ein Scribd-Unternehmen logo
1 von 47
FP7 2012 Health Call Overview Graham Hughes,  FP7UK NCP for Health (Industry)
[object Object],[object Object]
FP7 - €53 billion spend  2007 - 2013
Cooperation Theme
Cooperation Theme Basics ,[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],Health Theme Objectives
The Health Theme: Structure Activity 1: Biotechnology,  generic tools  & technologies  for health  Activity 2: Translating  research for human health   Activity 3: Optimising  the delivery  of health care  cross-cutting issues:   international cooperation, SMEs,  child  health,  ageing  populations,  gender -related health issues Activity 4:   Support actions & response to policy needs The Innovative Medicines Initiative
Health Theme Funding 2007 - 2013 Year Total Funding Projects Funded 2007 € 641 million 153 2008 € 577 million 172 2009 € 611 million 105 2010 € 621 million 131 2011 € 650 million ~126 2012 € 620 million ? 2013 € 780 million ?
UK Performance (Health Theme)  Health Funding totals 2007 -2009 – All  Participations
UK FP7 Health Theme  in Numbers* Submissions with UK partners  = 3264* Successful projects with UK partners = 859 UK coordinated submissions = 383 93 projects coordinated by UK partners *2007 – 2009 data – from  GAs and participants database (released on 1 May 2010 - data cut-off date 25 March 2010  52 UK SMEs in active FP7 projects (plus 17 new 2010)
SME Participation EU target of 15% funding to SME partners
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Collaborative Research: Why?
Collaborative Research: Who? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Collaborative Research: How?
WP First Draft Open day (Brussels)  09 June 2011  Call published Stage 1 Deadline NCP Roadshow Evaluation results Evaluation PC Meetings Collaborative Research: When?
Framework Programme 7 Support and Further Information Graham Hughes,  FP7UK NCP for Health (Industry)
Initial Considerations ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Key Tips ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Support and Further Information
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],NCP Support All advice is impartial, confidential and free
Support and Further Information ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Framework Programme 7 2012 Call Information Graham Hughes,  FP7UK NCP for Health (Industry)
2012 Call – Context ,[object Object],[object Object],[object Object],[object Object],[object Object]
2012 Call – Innovation Driven ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
2012 Call – Closed Areas ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
2012 Call Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
2012 Call – SME Focused ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],> 30% >15%
Health Theme Funding 2007 - 2013 Year Total Funding Projects Funded SME Targeted 2 Stage 2007 € 641 million 153 0% 0 2008 € 577 million 172 0% 0 2009 € 611 million 105 0% 0 2010 € 621 million 131 0% 19% 2011 € 650 million ~126 20% 75% 2012 € 620 million ? 53% 100% 2013 € 780 million ? ~ 50% 100%
2012 Call – Pilot SME Innovation Call  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],> 50%
2012 Call – Research Priorities #1 Ageing ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],EIP
2012 Call – Research Priorities #2 Medical Technologies ,[object Object],[object Object],[object Object],Tech
2012 Call – Research Priorities #3 Clinical Trials ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Clin
1.2: Detection, Diagnosis and Monitoring EIP > 30% ,[object Object],[object Object],[object Object],[object Object],[object Object],1.2.1 Development of technologies with a view to patient group stratification for personalised medicine applications 6,000,000 >1
1.4:  Innovative Therapeutic Approaches and Interventions >15% >15% EIP > 50% > 30% Tech Tech * 1.4-3 requires cooperation with Australia Clin Transplantation topics have not featured highly in FP7 to date  1.4-1 Innovative approaches to solid organ transplantation 6,000,000 >1 1.4-2 Medical technology for the transplantation sector and bioartificial organs 6,000,000 >1 1.4-3* Innovative strategies for translation of stem cell based therapies in regenerative medicine 6,000,000 1 1.4-4 Targeted nucleic acid delivery as an innovative therapeutic or prophylactic approach 6,000,000 >1
2.1.1:  Large Scale Data Gathering >15% EIP > 30% > 30% ,[object Object],[object Object],2.1.1.1-A Support for international rare disease research 2,000,000 1 2.1.1.1-B Clinical utility of -omics for better diagnosis of rare diseases 12,000,000 2 2.1.1.1-C Databases, biobanks and clinical bio-informatics' hub for rare diseases 12,000,000 1 2.1.1-2 Validation of -omics based biomarkers for diseases affecting the elderly 12,000,000 >1 2.1.1-3 Statistical methods for collection and analysis of -omics data 6,000,000 >1
2.1.2: Systems Biology ,[object Object],[object Object],[object Object],> 30% 2.1.2-1 Systems medicine: SME-driven research applying systems biology approaches to address clinical needs 3,000,000 >1 2.1.2-2 Systems medicine: Applying systems biology approaches for understanding common human diseases and their co-morbidities 12,000,000 >1 2.1.2-3 Preparing for the future research and innovation activities in systems medicine 3,000,000 1
2.2.2:  Human Development and Ageing >15% EIP EIP Clin > 30% ,[object Object],[object Object],2.2.2-1 Integrative systems biology and comparative genomics for studying human ageing and most common age-related conditions 6,000,000 >1 2.2.2-2 Investigator-driven clinical trials for optimisation of treatment for elderly patients with multiple diseases 6,000,000 >1
2.3.0:  Cross Cutting > 50% Tech ,[object Object],[object Object],[object Object],[object Object],2.3.0-1 Diagnostics for infectious diseases in humans 6,000,000 >1 2.3.0-2 ERA-NET on Infectious Diseases 2,000,000 1
2.3.2: HIV/AIDS Malaria and TB  ,[object Object],[object Object],[object Object],[object Object],>15% 2.3.2-1 Co-infection and co-morbidity in HIV/AIDS, malaria, tuberculosis and/or hepatitis 6,000,000 >1 2.3.2-2 Co-morbidity between infectious and non-communicable diseases 6,000,000 >1 2.3.2-3 Prevention and treatment for HIV/AIDS, malaria and tuberculosis 6,000,000 >1 2.3.2-4 Low-cost interventions for disease control in resource poor settings 3,000,000 >1
2.4.3:  Diabetes and Obesity Clin > 30% Tech 2.4.3-1 Innovative approach to manage diabetes 6,000,000 >1 2.4.3-2 Investigator-driven clinical trials for type 1 diabetes research 6,000,000 >1
2.4.4:  Rare Diseases Clin Clin > 30% 2.4.4-1 Preclinical and/or clinical development of substances with a clear potential as orphan drugs 6,000,000 >1 2.4.4-2 Observational trials in rare diseases 3,000,000 >1 2.4.4-3 Best practice and knowledge sharing in the clinical management of rare diseases 2,000,000 1
2.4.5:  Other Chronic Diseases EIP > 50% >15% EIP Tech Tech 2.4.5-1 Technological approaches to to combating sensory impairments 6,000,000 >1 2.4.5-2 Biomarkers and diagnostics for chronic inflammatory diseases of the joints 6,000,000 >1
2012 Call – Healthcare Delivery ,[object Object],[object Object],[object Object],EIP EIP Tech 3.2-1 Improving the organisation of health service delivery 3,000,000 >1 3.2-2 New methodologies for health technology assessment 3,000,000 >1 3.2-2 Social Innovation platform for ageing research 6,000,000 1 3.4-1 Health systems/services research in low and middle income countries 6,000,000 >1
2012 Call – Coordination and Support Actions ,[object Object],4.1-1 Network to encourage technology transfer in FP-funded health research (especially in academic and governmental organisations) 2,000,000 1 4.1-2 Training actions linked to intellectual property rights management and technology transfer 2,000,000 1 4.1-3 Support for Presidency events: Organisation of supporting actions and events related to the Presidency of the European Union 100,000 >1 4.1-4 Communicating the benefits of European research to the general public 1,000,000 >1 4.1-5 Preparing for the future for health research and innovation 500,000 >1
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Key Dates
Other Health Related EU Funding Sources 2011  Nanosciences, Materials and Production  NMP NMP.2012.1.2-2: Development and phase-I clinical trials of novel therapeutic nanotechnology-enabled systems for the diagnosis and treatment of atherosclerosis NMP.2012.2.2-1: Biomaterials for improved performance of medical implants Likely timeframe similar to Health call
Other Health Related EU Funding Sources 2011  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Weitere ähnliche Inhalte

Was ist angesagt?

Campus in Innovation by Ideas
Campus in Innovation by IdeasCampus in Innovation by Ideas
Campus in Innovation by IdeasEITHEALTH
 
ERC Seminar presentation. 14.02.2017. Areti Gykpali
ERC Seminar presentation. 14.02.2017. Areti GykpaliERC Seminar presentation. 14.02.2017. Areti Gykpali
ERC Seminar presentation. 14.02.2017. Areti Gykpalienterpriseresearchcentre
 
Results of the EUnetHTA Joint Action
Results of the EUnetHTA Joint ActionResults of the EUnetHTA Joint Action
Results of the EUnetHTA Joint ActionEUnetHTA
 
eGovernment research in the EU member states
eGovernment research in the EU member stateseGovernment research in the EU member states
eGovernment research in the EU member statesosimod
 
Horizon2020 - Stimulating Research and Innovation Investments for Growth and ...
Horizon2020 - Stimulating Research and Innovation Investments for Growth and ...Horizon2020 - Stimulating Research and Innovation Investments for Growth and ...
Horizon2020 - Stimulating Research and Innovation Investments for Growth and ...Invest Northern Ireland
 
Research funding and research management - FP7 & H2020
Research funding and research management - FP7 & H2020Research funding and research management - FP7 & H2020
Research funding and research management - FP7 & H2020Elena Petelos
 
EuroBioForum 2013 - Day 1 | Wolfgang Eberle
 EuroBioForum 2013 - Day 1 | Wolfgang Eberle EuroBioForum 2013 - Day 1 | Wolfgang Eberle
EuroBioForum 2013 - Day 1 | Wolfgang EberleEuroBioForum
 
How can patients and providers best contribute to the HTA process?
How can patients and providers best contribute to the HTA process?How can patients and providers best contribute to the HTA process?
How can patients and providers best contribute to the HTA process?EUnetHTA
 
Sustainability of research centres – key challenges and approaches
Sustainability of research centres – key challenges and approachesSustainability of research centres – key challenges and approaches
Sustainability of research centres – key challenges and approachesRichard O'Connell
 
Performance Monitoring Report of the EU Programme for Employment and Social I...
Performance Monitoring Report of the EU Programme for Employment and Social I...Performance Monitoring Report of the EU Programme for Employment and Social I...
Performance Monitoring Report of the EU Programme for Employment and Social I...Mantas Pupinis
 
Product Development Partnership 2014
Product Development Partnership 2014Product Development Partnership 2014
Product Development Partnership 2014isilguney
 
Ian Holmes: Innovate UK Support for H2020 Collaboration
Ian Holmes: Innovate UK Support for H2020 CollaborationIan Holmes: Innovate UK Support for H2020 Collaboration
Ian Holmes: Innovate UK Support for H2020 CollaborationBusiness Innovation Network
 
PNO - Open Science EU (June 2016, final version)
PNO - Open Science EU (June 2016, final version)PNO - Open Science EU (June 2016, final version)
PNO - Open Science EU (June 2016, final version)James Hughes
 
How to use the EUnetHTA submission template to support production of core Hea...
How to use the EUnetHTA submission template to support production of core Hea...How to use the EUnetHTA submission template to support production of core Hea...
How to use the EUnetHTA submission template to support production of core Hea...EUnetHTA
 
Presentation Vva Europe
Presentation Vva EuropePresentation Vva Europe
Presentation Vva Europehausemp
 
Slides eurofound - innovation and employment - 13 feb 19
Slides   eurofound - innovation and employment - 13 feb 19Slides   eurofound - innovation and employment - 13 feb 19
Slides eurofound - innovation and employment - 13 feb 19NevinInstitute
 
Cadth 2015 d2 warren cadth april_14_2015
Cadth 2015 d2 warren cadth april_14_2015Cadth 2015 d2 warren cadth april_14_2015
Cadth 2015 d2 warren cadth april_14_2015CADTH Symposium
 

Was ist angesagt? (20)

COASP Spichtinger
COASP SpichtingerCOASP Spichtinger
COASP Spichtinger
 
Campus in Innovation by Ideas
Campus in Innovation by IdeasCampus in Innovation by Ideas
Campus in Innovation by Ideas
 
ERC Seminar presentation. 14.02.2017. Areti Gykpali
ERC Seminar presentation. 14.02.2017. Areti GykpaliERC Seminar presentation. 14.02.2017. Areti Gykpali
ERC Seminar presentation. 14.02.2017. Areti Gykpali
 
Results of the EUnetHTA Joint Action
Results of the EUnetHTA Joint ActionResults of the EUnetHTA Joint Action
Results of the EUnetHTA Joint Action
 
eGovernment research in the EU member states
eGovernment research in the EU member stateseGovernment research in the EU member states
eGovernment research in the EU member states
 
EIT Health Presentation | CRAASH Barcelona
EIT Health Presentation | CRAASH BarcelonaEIT Health Presentation | CRAASH Barcelona
EIT Health Presentation | CRAASH Barcelona
 
Horizon2020 - Stimulating Research and Innovation Investments for Growth and ...
Horizon2020 - Stimulating Research and Innovation Investments for Growth and ...Horizon2020 - Stimulating Research and Innovation Investments for Growth and ...
Horizon2020 - Stimulating Research and Innovation Investments for Growth and ...
 
Research funding and research management - FP7 & H2020
Research funding and research management - FP7 & H2020Research funding and research management - FP7 & H2020
Research funding and research management - FP7 & H2020
 
EuroBioForum 2013 - Day 1 | Wolfgang Eberle
 EuroBioForum 2013 - Day 1 | Wolfgang Eberle EuroBioForum 2013 - Day 1 | Wolfgang Eberle
EuroBioForum 2013 - Day 1 | Wolfgang Eberle
 
How can patients and providers best contribute to the HTA process?
How can patients and providers best contribute to the HTA process?How can patients and providers best contribute to the HTA process?
How can patients and providers best contribute to the HTA process?
 
Health Technology Assessment (HTA): a tool for evidence-informed decision mak...
Health Technology Assessment (HTA): a tool for evidence-informed decision mak...Health Technology Assessment (HTA): a tool for evidence-informed decision mak...
Health Technology Assessment (HTA): a tool for evidence-informed decision mak...
 
Sustainability of research centres – key challenges and approaches
Sustainability of research centres – key challenges and approachesSustainability of research centres – key challenges and approaches
Sustainability of research centres – key challenges and approaches
 
Performance Monitoring Report of the EU Programme for Employment and Social I...
Performance Monitoring Report of the EU Programme for Employment and Social I...Performance Monitoring Report of the EU Programme for Employment and Social I...
Performance Monitoring Report of the EU Programme for Employment and Social I...
 
Product Development Partnership 2014
Product Development Partnership 2014Product Development Partnership 2014
Product Development Partnership 2014
 
Ian Holmes: Innovate UK Support for H2020 Collaboration
Ian Holmes: Innovate UK Support for H2020 CollaborationIan Holmes: Innovate UK Support for H2020 Collaboration
Ian Holmes: Innovate UK Support for H2020 Collaboration
 
PNO - Open Science EU (June 2016, final version)
PNO - Open Science EU (June 2016, final version)PNO - Open Science EU (June 2016, final version)
PNO - Open Science EU (June 2016, final version)
 
How to use the EUnetHTA submission template to support production of core Hea...
How to use the EUnetHTA submission template to support production of core Hea...How to use the EUnetHTA submission template to support production of core Hea...
How to use the EUnetHTA submission template to support production of core Hea...
 
Presentation Vva Europe
Presentation Vva EuropePresentation Vva Europe
Presentation Vva Europe
 
Slides eurofound - innovation and employment - 13 feb 19
Slides   eurofound - innovation and employment - 13 feb 19Slides   eurofound - innovation and employment - 13 feb 19
Slides eurofound - innovation and employment - 13 feb 19
 
Cadth 2015 d2 warren cadth april_14_2015
Cadth 2015 d2 warren cadth april_14_2015Cadth 2015 d2 warren cadth april_14_2015
Cadth 2015 d2 warren cadth april_14_2015
 

Ähnlich wie Graham Hughes - Beta Technology - FP 7 Call Presentation

HORIZON 2020 Overview - Robert-Jan Smits - Presentation - Israel 3.2.2014
HORIZON 2020 Overview - Robert-Jan Smits - Presentation - Israel 3.2.2014HORIZON 2020 Overview - Robert-Jan Smits - Presentation - Israel 3.2.2014
HORIZON 2020 Overview - Robert-Jan Smits - Presentation - Israel 3.2.2014ISERD Israel
 
Horizon 2020 - Alain Thielemans
Horizon 2020 - Alain ThielemansHorizon 2020 - Alain Thielemans
Horizon 2020 - Alain Thielemansimec
 
EuroBioForum2014_speaker_Adami
EuroBioForum2014_speaker_AdamiEuroBioForum2014_speaker_Adami
EuroBioForum2014_speaker_AdamiEuroBioForum
 
horizon2020-presentation
horizon2020-presentationhorizon2020-presentation
horizon2020-presentationEmilio Mulet
 
Overview of Horizon Europe Clusters - Webinar Series | Health (Cluster 1)
Overview of Horizon Europe Clusters - Webinar Series | Health (Cluster 1)Overview of Horizon Europe Clusters - Webinar Series | Health (Cluster 1)
Overview of Horizon Europe Clusters - Webinar Series | Health (Cluster 1)KTN
 
Horizon 2020 for SMEs - ttopstart, the Horizon 2020 experts
Horizon 2020 for SMEs - ttopstart, the Horizon 2020 expertsHorizon 2020 for SMEs - ttopstart, the Horizon 2020 experts
Horizon 2020 for SMEs - ttopstart, the Horizon 2020 expertsttopstart B.V.
 
Partnership as the driver of R&D and innovation
Partnership as the driver of R&D and innovationPartnership as the driver of R&D and innovation
Partnership as the driver of R&D and innovationSteve Rogers
 
Zilgalvis, Peteris - Sustainability Through Innovative. Partnerships: Global ...
Zilgalvis, Peteris - Sustainability Through Innovative. Partnerships: Global ...Zilgalvis, Peteris - Sustainability Through Innovative. Partnerships: Global ...
Zilgalvis, Peteris - Sustainability Through Innovative. Partnerships: Global ...ponencias_mihealth2012
 
Tue 14 jun ilias eu-us- 14-6-11
Tue 14 jun ilias   eu-us- 14-6-11Tue 14 jun ilias   eu-us- 14-6-11
Tue 14 jun ilias eu-us- 14-6-113GDR
 
IMI Graham Hughes
IMI Graham HughesIMI Graham Hughes
IMI Graham HughesCK Group
 
Trends and innovation needs in the european food and drink industry
Trends and innovation needs in the european food and drink industryTrends and innovation needs in the european food and drink industry
Trends and innovation needs in the european food and drink industryNikos Giannoulidis
 
Tackling societal challenges through digital transformation
Tackling societal challenges through digital transformationTackling societal challenges through digital transformation
Tackling societal challenges through digital transformationGames for Health Europe
 
Horizon 2020: Funding opportunities for academic & business research partners...
Horizon 2020: Funding opportunities for academic & business research partners...Horizon 2020: Funding opportunities for academic & business research partners...
Horizon 2020: Funding opportunities for academic & business research partners...Iraklis Agiovlasitis
 
Anaxo1wwwwwwwww
Anaxo1wwwwwwwwwAnaxo1wwwwwwwww
Anaxo1wwwwwwwwwamautajara
 
EU health research funding opportunities
EU health research funding opportunitiesEU health research funding opportunities
EU health research funding opportunitiesdoctrid2012
 
Priorités thématiques et dimension internationale du projet H2020
Priorités thématiques et dimension internationale du projet H2020Priorités thématiques et dimension internationale du projet H2020
Priorités thématiques et dimension internationale du projet H2020Pasteur_Tunis
 

Ähnlich wie Graham Hughes - Beta Technology - FP 7 Call Presentation (20)

HORIZON 2020 Overview - Robert-Jan Smits - Presentation - Israel 3.2.2014
HORIZON 2020 Overview - Robert-Jan Smits - Presentation - Israel 3.2.2014HORIZON 2020 Overview - Robert-Jan Smits - Presentation - Israel 3.2.2014
HORIZON 2020 Overview - Robert-Jan Smits - Presentation - Israel 3.2.2014
 
Horizon 2020 - Alain Thielemans
Horizon 2020 - Alain ThielemansHorizon 2020 - Alain Thielemans
Horizon 2020 - Alain Thielemans
 
10.richard burger
10.richard burger10.richard burger
10.richard burger
 
EuroBioForum2014_speaker_Adami
EuroBioForum2014_speaker_AdamiEuroBioForum2014_speaker_Adami
EuroBioForum2014_speaker_Adami
 
20070115 FP7 Info
20070115 FP7 Info20070115 FP7 Info
20070115 FP7 Info
 
Horizon 2020 Presentation
Horizon 2020 PresentationHorizon 2020 Presentation
Horizon 2020 Presentation
 
horizon2020-presentation
horizon2020-presentationhorizon2020-presentation
horizon2020-presentation
 
Overview of Horizon Europe Clusters - Webinar Series | Health (Cluster 1)
Overview of Horizon Europe Clusters - Webinar Series | Health (Cluster 1)Overview of Horizon Europe Clusters - Webinar Series | Health (Cluster 1)
Overview of Horizon Europe Clusters - Webinar Series | Health (Cluster 1)
 
Horizon 2020 for SMEs - ttopstart, the Horizon 2020 experts
Horizon 2020 for SMEs - ttopstart, the Horizon 2020 expertsHorizon 2020 for SMEs - ttopstart, the Horizon 2020 experts
Horizon 2020 for SMEs - ttopstart, the Horizon 2020 experts
 
Partnership as the driver of R&D and innovation
Partnership as the driver of R&D and innovationPartnership as the driver of R&D and innovation
Partnership as the driver of R&D and innovation
 
Zilgalvis, Peteris - Sustainability Through Innovative. Partnerships: Global ...
Zilgalvis, Peteris - Sustainability Through Innovative. Partnerships: Global ...Zilgalvis, Peteris - Sustainability Through Innovative. Partnerships: Global ...
Zilgalvis, Peteris - Sustainability Through Innovative. Partnerships: Global ...
 
Tue 14 jun ilias eu-us- 14-6-11
Tue 14 jun ilias   eu-us- 14-6-11Tue 14 jun ilias   eu-us- 14-6-11
Tue 14 jun ilias eu-us- 14-6-11
 
IMI Graham Hughes
IMI Graham HughesIMI Graham Hughes
IMI Graham Hughes
 
Trends and innovation needs in the european food and drink industry
Trends and innovation needs in the european food and drink industryTrends and innovation needs in the european food and drink industry
Trends and innovation needs in the european food and drink industry
 
2.tic sante atelierh2020- pcn santé-10sept15
2.tic sante atelierh2020- pcn santé-10sept152.tic sante atelierh2020- pcn santé-10sept15
2.tic sante atelierh2020- pcn santé-10sept15
 
Tackling societal challenges through digital transformation
Tackling societal challenges through digital transformationTackling societal challenges through digital transformation
Tackling societal challenges through digital transformation
 
Horizon 2020: Funding opportunities for academic & business research partners...
Horizon 2020: Funding opportunities for academic & business research partners...Horizon 2020: Funding opportunities for academic & business research partners...
Horizon 2020: Funding opportunities for academic & business research partners...
 
Anaxo1wwwwwwwww
Anaxo1wwwwwwwwwAnaxo1wwwwwwwww
Anaxo1wwwwwwwww
 
EU health research funding opportunities
EU health research funding opportunitiesEU health research funding opportunities
EU health research funding opportunities
 
Priorités thématiques et dimension internationale du projet H2020
Priorités thématiques et dimension internationale du projet H2020Priorités thématiques et dimension internationale du projet H2020
Priorités thématiques et dimension internationale du projet H2020
 

Mehr von CK Group

CK Clinical - Medics Advert
CK Clinical - Medics AdvertCK Clinical - Medics Advert
CK Clinical - Medics AdvertCK Group
 
CK Aspire Brochure
CK Aspire BrochureCK Aspire Brochure
CK Aspire BrochureCK Group
 
CK Science Biocity Advert
CK Science Biocity AdvertCK Science Biocity Advert
CK Science Biocity AdvertCK Group
 
CK Science Brochure
CK Science BrochureCK Science Brochure
CK Science BrochureCK Group
 
CK Science - Chemical Recruitment
CK Science - Chemical RecruitmentCK Science - Chemical Recruitment
CK Science - Chemical RecruitmentCK Group
 
CK Group Brochure - Scientific, Clinical and IT Recruitment
CK Group Brochure - Scientific, Clinical and IT RecruitmentCK Group Brochure - Scientific, Clinical and IT Recruitment
CK Group Brochure - Scientific, Clinical and IT RecruitmentCK Group
 
CK Clinical Europe Flyer
CK Clinical Europe FlyerCK Clinical Europe Flyer
CK Clinical Europe FlyerCK Group
 
CK Group Advert February 2012
CK Group Advert February 2012CK Group Advert February 2012
CK Group Advert February 2012CK Group
 
Roche Statistical Programming Brochure
Roche Statistical Programming BrochureRoche Statistical Programming Brochure
Roche Statistical Programming BrochureCK Group
 
CK Clinical Job Hunting Workshop
CK Clinical Job Hunting WorkshopCK Clinical Job Hunting Workshop
CK Clinical Job Hunting WorkshopCK Group
 
Steve Bradley - FP7 Beta Technology Presentation
Steve Bradley - FP7 Beta Technology PresentationSteve Bradley - FP7 Beta Technology Presentation
Steve Bradley - FP7 Beta Technology PresentationCK Group
 
Simcyp Presentation - Rebecca Martell
Simcyp Presentation - Rebecca MartellSimcyp Presentation - Rebecca Martell
Simcyp Presentation - Rebecca MartellCK Group
 
HR in Pharma Networking Event - Mike Taylor
HR in Pharma Networking Event - Mike TaylorHR in Pharma Networking Event - Mike Taylor
HR in Pharma Networking Event - Mike TaylorCK Group
 
HR in Pharma Networking Event - Fiona Coombe
HR in Pharma Networking Event - Fiona Coombe HR in Pharma Networking Event - Fiona Coombe
HR in Pharma Networking Event - Fiona Coombe CK Group
 

Mehr von CK Group (14)

CK Clinical - Medics Advert
CK Clinical - Medics AdvertCK Clinical - Medics Advert
CK Clinical - Medics Advert
 
CK Aspire Brochure
CK Aspire BrochureCK Aspire Brochure
CK Aspire Brochure
 
CK Science Biocity Advert
CK Science Biocity AdvertCK Science Biocity Advert
CK Science Biocity Advert
 
CK Science Brochure
CK Science BrochureCK Science Brochure
CK Science Brochure
 
CK Science - Chemical Recruitment
CK Science - Chemical RecruitmentCK Science - Chemical Recruitment
CK Science - Chemical Recruitment
 
CK Group Brochure - Scientific, Clinical and IT Recruitment
CK Group Brochure - Scientific, Clinical and IT RecruitmentCK Group Brochure - Scientific, Clinical and IT Recruitment
CK Group Brochure - Scientific, Clinical and IT Recruitment
 
CK Clinical Europe Flyer
CK Clinical Europe FlyerCK Clinical Europe Flyer
CK Clinical Europe Flyer
 
CK Group Advert February 2012
CK Group Advert February 2012CK Group Advert February 2012
CK Group Advert February 2012
 
Roche Statistical Programming Brochure
Roche Statistical Programming BrochureRoche Statistical Programming Brochure
Roche Statistical Programming Brochure
 
CK Clinical Job Hunting Workshop
CK Clinical Job Hunting WorkshopCK Clinical Job Hunting Workshop
CK Clinical Job Hunting Workshop
 
Steve Bradley - FP7 Beta Technology Presentation
Steve Bradley - FP7 Beta Technology PresentationSteve Bradley - FP7 Beta Technology Presentation
Steve Bradley - FP7 Beta Technology Presentation
 
Simcyp Presentation - Rebecca Martell
Simcyp Presentation - Rebecca MartellSimcyp Presentation - Rebecca Martell
Simcyp Presentation - Rebecca Martell
 
HR in Pharma Networking Event - Mike Taylor
HR in Pharma Networking Event - Mike TaylorHR in Pharma Networking Event - Mike Taylor
HR in Pharma Networking Event - Mike Taylor
 
HR in Pharma Networking Event - Fiona Coombe
HR in Pharma Networking Event - Fiona Coombe HR in Pharma Networking Event - Fiona Coombe
HR in Pharma Networking Event - Fiona Coombe
 

Kürzlich hochgeladen

The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptxThe Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptxLoriGlavin3
 
Ensuring Technical Readiness For Copilot in Microsoft 365
Ensuring Technical Readiness For Copilot in Microsoft 365Ensuring Technical Readiness For Copilot in Microsoft 365
Ensuring Technical Readiness For Copilot in Microsoft 3652toLead Limited
 
What is Artificial Intelligence?????????
What is Artificial Intelligence?????????What is Artificial Intelligence?????????
What is Artificial Intelligence?????????blackmambaettijean
 
DSPy a system for AI to Write Prompts and Do Fine Tuning
DSPy a system for AI to Write Prompts and Do Fine TuningDSPy a system for AI to Write Prompts and Do Fine Tuning
DSPy a system for AI to Write Prompts and Do Fine TuningLars Bell
 
Gen AI in Business - Global Trends Report 2024.pdf
Gen AI in Business - Global Trends Report 2024.pdfGen AI in Business - Global Trends Report 2024.pdf
Gen AI in Business - Global Trends Report 2024.pdfAddepto
 
SALESFORCE EDUCATION CLOUD | FEXLE SERVICES
SALESFORCE EDUCATION CLOUD | FEXLE SERVICESSALESFORCE EDUCATION CLOUD | FEXLE SERVICES
SALESFORCE EDUCATION CLOUD | FEXLE SERVICESmohitsingh558521
 
Sample pptx for embedding into website for demo
Sample pptx for embedding into website for demoSample pptx for embedding into website for demo
Sample pptx for embedding into website for demoHarshalMandlekar2
 
New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024BookNet Canada
 
How AI, OpenAI, and ChatGPT impact business and software.
How AI, OpenAI, and ChatGPT impact business and software.How AI, OpenAI, and ChatGPT impact business and software.
How AI, OpenAI, and ChatGPT impact business and software.Curtis Poe
 
The Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptx
The Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptxThe Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptx
The Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptxLoriGlavin3
 
Merck Moving Beyond Passwords: FIDO Paris Seminar.pptx
Merck Moving Beyond Passwords: FIDO Paris Seminar.pptxMerck Moving Beyond Passwords: FIDO Paris Seminar.pptx
Merck Moving Beyond Passwords: FIDO Paris Seminar.pptxLoriGlavin3
 
Take control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteTake control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteDianaGray10
 
How to write a Business Continuity Plan
How to write a Business Continuity PlanHow to write a Business Continuity Plan
How to write a Business Continuity PlanDatabarracks
 
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)Mark Simos
 
"Subclassing and Composition – A Pythonic Tour of Trade-Offs", Hynek Schlawack
"Subclassing and Composition – A Pythonic Tour of Trade-Offs", Hynek Schlawack"Subclassing and Composition – A Pythonic Tour of Trade-Offs", Hynek Schlawack
"Subclassing and Composition – A Pythonic Tour of Trade-Offs", Hynek SchlawackFwdays
 
Digital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptxDigital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptxLoriGlavin3
 
DevEX - reference for building teams, processes, and platforms
DevEX - reference for building teams, processes, and platformsDevEX - reference for building teams, processes, and platforms
DevEX - reference for building teams, processes, and platformsSergiu Bodiu
 
The Ultimate Guide to Choosing WordPress Pros and Cons
The Ultimate Guide to Choosing WordPress Pros and ConsThe Ultimate Guide to Choosing WordPress Pros and Cons
The Ultimate Guide to Choosing WordPress Pros and ConsPixlogix Infotech
 
What's New in Teams Calling, Meetings and Devices March 2024
What's New in Teams Calling, Meetings and Devices March 2024What's New in Teams Calling, Meetings and Devices March 2024
What's New in Teams Calling, Meetings and Devices March 2024Stephanie Beckett
 
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024BookNet Canada
 

Kürzlich hochgeladen (20)

The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptxThe Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
 
Ensuring Technical Readiness For Copilot in Microsoft 365
Ensuring Technical Readiness For Copilot in Microsoft 365Ensuring Technical Readiness For Copilot in Microsoft 365
Ensuring Technical Readiness For Copilot in Microsoft 365
 
What is Artificial Intelligence?????????
What is Artificial Intelligence?????????What is Artificial Intelligence?????????
What is Artificial Intelligence?????????
 
DSPy a system for AI to Write Prompts and Do Fine Tuning
DSPy a system for AI to Write Prompts and Do Fine TuningDSPy a system for AI to Write Prompts and Do Fine Tuning
DSPy a system for AI to Write Prompts and Do Fine Tuning
 
Gen AI in Business - Global Trends Report 2024.pdf
Gen AI in Business - Global Trends Report 2024.pdfGen AI in Business - Global Trends Report 2024.pdf
Gen AI in Business - Global Trends Report 2024.pdf
 
SALESFORCE EDUCATION CLOUD | FEXLE SERVICES
SALESFORCE EDUCATION CLOUD | FEXLE SERVICESSALESFORCE EDUCATION CLOUD | FEXLE SERVICES
SALESFORCE EDUCATION CLOUD | FEXLE SERVICES
 
Sample pptx for embedding into website for demo
Sample pptx for embedding into website for demoSample pptx for embedding into website for demo
Sample pptx for embedding into website for demo
 
New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
 
How AI, OpenAI, and ChatGPT impact business and software.
How AI, OpenAI, and ChatGPT impact business and software.How AI, OpenAI, and ChatGPT impact business and software.
How AI, OpenAI, and ChatGPT impact business and software.
 
The Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptx
The Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptxThe Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptx
The Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptx
 
Merck Moving Beyond Passwords: FIDO Paris Seminar.pptx
Merck Moving Beyond Passwords: FIDO Paris Seminar.pptxMerck Moving Beyond Passwords: FIDO Paris Seminar.pptx
Merck Moving Beyond Passwords: FIDO Paris Seminar.pptx
 
Take control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteTake control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test Suite
 
How to write a Business Continuity Plan
How to write a Business Continuity PlanHow to write a Business Continuity Plan
How to write a Business Continuity Plan
 
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
 
"Subclassing and Composition – A Pythonic Tour of Trade-Offs", Hynek Schlawack
"Subclassing and Composition – A Pythonic Tour of Trade-Offs", Hynek Schlawack"Subclassing and Composition – A Pythonic Tour of Trade-Offs", Hynek Schlawack
"Subclassing and Composition – A Pythonic Tour of Trade-Offs", Hynek Schlawack
 
Digital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptxDigital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptx
 
DevEX - reference for building teams, processes, and platforms
DevEX - reference for building teams, processes, and platformsDevEX - reference for building teams, processes, and platforms
DevEX - reference for building teams, processes, and platforms
 
The Ultimate Guide to Choosing WordPress Pros and Cons
The Ultimate Guide to Choosing WordPress Pros and ConsThe Ultimate Guide to Choosing WordPress Pros and Cons
The Ultimate Guide to Choosing WordPress Pros and Cons
 
What's New in Teams Calling, Meetings and Devices March 2024
What's New in Teams Calling, Meetings and Devices March 2024What's New in Teams Calling, Meetings and Devices March 2024
What's New in Teams Calling, Meetings and Devices March 2024
 
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
 

Graham Hughes - Beta Technology - FP 7 Call Presentation

  • 1. FP7 2012 Health Call Overview Graham Hughes, FP7UK NCP for Health (Industry)
  • 2.
  • 3. FP7 - €53 billion spend 2007 - 2013
  • 5.
  • 6.
  • 7. The Health Theme: Structure Activity 1: Biotechnology, generic tools & technologies for health Activity 2: Translating research for human health Activity 3: Optimising the delivery of health care cross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender -related health issues Activity 4: Support actions & response to policy needs The Innovative Medicines Initiative
  • 8. Health Theme Funding 2007 - 2013 Year Total Funding Projects Funded 2007 € 641 million 153 2008 € 577 million 172 2009 € 611 million 105 2010 € 621 million 131 2011 € 650 million ~126 2012 € 620 million ? 2013 € 780 million ?
  • 9. UK Performance (Health Theme) Health Funding totals 2007 -2009 – All Participations
  • 10. UK FP7 Health Theme in Numbers* Submissions with UK partners = 3264* Successful projects with UK partners = 859 UK coordinated submissions = 383 93 projects coordinated by UK partners *2007 – 2009 data – from GAs and participants database (released on 1 May 2010 - data cut-off date 25 March 2010 52 UK SMEs in active FP7 projects (plus 17 new 2010)
  • 11. SME Participation EU target of 15% funding to SME partners
  • 12.
  • 13.
  • 14.
  • 15. WP First Draft Open day (Brussels) 09 June 2011 Call published Stage 1 Deadline NCP Roadshow Evaluation results Evaluation PC Meetings Collaborative Research: When?
  • 16. Framework Programme 7 Support and Further Information Graham Hughes, FP7UK NCP for Health (Industry)
  • 17.
  • 18.
  • 19. Support and Further Information
  • 20.
  • 21.
  • 22. Framework Programme 7 2012 Call Information Graham Hughes, FP7UK NCP for Health (Industry)
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28. Health Theme Funding 2007 - 2013 Year Total Funding Projects Funded SME Targeted 2 Stage 2007 € 641 million 153 0% 0 2008 € 577 million 172 0% 0 2009 € 611 million 105 0% 0 2010 € 621 million 131 0% 19% 2011 € 650 million ~126 20% 75% 2012 € 620 million ? 53% 100% 2013 € 780 million ? ~ 50% 100%
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34. 1.4: Innovative Therapeutic Approaches and Interventions >15% >15% EIP > 50% > 30% Tech Tech * 1.4-3 requires cooperation with Australia Clin Transplantation topics have not featured highly in FP7 to date 1.4-1 Innovative approaches to solid organ transplantation 6,000,000 >1 1.4-2 Medical technology for the transplantation sector and bioartificial organs 6,000,000 >1 1.4-3* Innovative strategies for translation of stem cell based therapies in regenerative medicine 6,000,000 1 1.4-4 Targeted nucleic acid delivery as an innovative therapeutic or prophylactic approach 6,000,000 >1
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40. 2.4.3: Diabetes and Obesity Clin > 30% Tech 2.4.3-1 Innovative approach to manage diabetes 6,000,000 >1 2.4.3-2 Investigator-driven clinical trials for type 1 diabetes research 6,000,000 >1
  • 41. 2.4.4: Rare Diseases Clin Clin > 30% 2.4.4-1 Preclinical and/or clinical development of substances with a clear potential as orphan drugs 6,000,000 >1 2.4.4-2 Observational trials in rare diseases 3,000,000 >1 2.4.4-3 Best practice and knowledge sharing in the clinical management of rare diseases 2,000,000 1
  • 42. 2.4.5: Other Chronic Diseases EIP > 50% >15% EIP Tech Tech 2.4.5-1 Technological approaches to to combating sensory impairments 6,000,000 >1 2.4.5-2 Biomarkers and diagnostics for chronic inflammatory diseases of the joints 6,000,000 >1
  • 43.
  • 44.
  • 45.
  • 46. Other Health Related EU Funding Sources 2011 Nanosciences, Materials and Production NMP NMP.2012.1.2-2: Development and phase-I clinical trials of novel therapeutic nanotechnology-enabled systems for the diagnosis and treatment of atherosclerosis NMP.2012.2.2-1: Biomaterials for improved performance of medical implants Likely timeframe similar to Health call
  • 47.

Hinweis der Redaktion

  1. Introduce myself work for Beta Technology contracted to TSB to provide the NCP service for the UK (Health) NCP role support for institutions wanting to access EU funding through the framework programme. publicity, advice, support, facilitation Ascertain how many have heard of Framework program
  2. So how is the Framework Program structured? First of all it is broken down into the major themes. Cooperation : the one we are most interested in and the core of FP7. It is designed to foster collaborative research across Europe and other partner countries through funded projects performed by transnational consortia of industry and academia Ideas: this theme supports frontier research solely on the basis of scientific excellence. Covers any area of science and technology, including socio-economic sciences and humanities. No obligation for cross-border partnerships – projects performed around individual teams. Implemented under the new European Research Council People : provides support for researcher mobility and career development both within the EU and internationally. Can provide initial training, industry-academia partnerships, funding of regional, national and international mobility programs. Capacities : designed to strengthen the research capacities that Europe needs to become a knowledge based economy. Programmes support research infrastructure with specific funding of projects by SMEs across a wide range of disciplines. Nuclear Research : lumps together all nuclear research including fusion energy, radiation protection, nuclear waste, support for EU policy making
  3. Let’s now focus on the Cooperation Theme, which attracts 60% of all Framework funding. It is broken down into ten different Program areas, each of which is allocated its own budget. Can see that the two biggest tranches of money are given to ICT and Health. Research activities in all these Program areas are driven by yearly “top down” calls for projects which describe specific topics and research areas. Projects are invited from trans-national consortia that meet the scope of the individual topic areas. There are, unfortunately a complex set of rules that these projects must follow, based around the project type, the construction of the consortium and the specific funding scheme that is determined for each subject. Not going to go into that detail now. A portion of the budget allocation for each programme is allocated with each call, for example this year the Health call was worth €651 million
  4. So what are the benefits of participation? There are a number, as shown here. Access to new networks and contacts – once in a consiortium can leverage the additional networks from other partners Money, obviously. Funding of a project could release resources for other activities. Profile ; increased visibility across the European stage could lead to further opportunities.
  5. So what are the benefits of participation? There are a number, as shown here. Access to new networks and contacts – once in a consiortium can leverage the additional networks from other partners Money, obviously. Funding of a project could release resources for other activities. Profile ; increased visibility across the European stage could lead to further opportunities.
  6. Again, the aim is to promote co-operation both trans-nationally within Europe and internationally so the programmes are usually open to a wide range of countries: EU Member States – have broadest rights and access Associated Countries, those with close associations with EC or seeking membership ICPCs – specific countries or groups of countries that receive preference for specific call topics Industrialised high income countries can participate but generally these will be expected to finance themselves The funding structure of the individual calls will specify specific conditions depending upon the nature of the topic but the basic rule is that there should be a minimum of three different legal entities from three different member states making up the core of the consortium.
  7. Again, the aim is to promote co-operation both trans-nationally within Europe and internationally so the programmes are usually open to a wide range of countries: EU Member States – have broadest rights and access Associated Countries, those with close associations with EC or seeking membership ICPCs – specific countries or groups of countries that receive preference for specific call topics Industrialised high income countries can participate but generally these will be expected to finance themselves The funding structure of the individual calls will specify specific conditions depending upon the nature of the topic but the basic rule is that there should be a minimum of three different legal entities from three different member states making up the core of the consortium.
  8. Introduce myself work for Beta Technology contracted to TSB to provide the NCP service for the UK (Health) NCP role support for institutions wanting to access EU funding through the framework programme. publicity, advice, support, facilitation Ascertain how many have heard of Framework program
  9. Introduce myself work for Beta Technology contracted to TSB to provide the NCP service for the UK (Health) NCP role support for institutions wanting to access EU funding through the framework programme. publicity, advice, support, facilitation Ascertain how many have heard of Framework program
  10. Always informative to see what factors are driving the direction of the WP Part of the Europe 2020 growth strategy with 5 key targets 75% of 20 – 64 age group in employment 3% GDP spent on R&D Greenhouse gas emissions 20% lower than 1990 School drop out rates < 10% 20 million fewer people in poverty The Innovation Union aims to improve conditions and access to finance for research and innovation in Europe, to ensure that innovative ideas can be turned into products and services that create growth and jobs.
  11. Starred topic areas have been closed for two successive calls
  12. Going to cover call topics by sub theme and call priority. Some will fall into two or even three categories so may repeat Don’t have time to go through each one in detail. If you identify any that you are interested in make a note then contact me or Vic to get details or discuss in detail.
  13. Emphesise 100% two stage call